S1 Clinical diabetes and therapeutics 1 :
Updates on new drugs for type 2 diabetes
Friday 14 October 09:00~11:00 | Place: Convention hall A
Chairs: Moon-Gi Choi, In-Kyung Jeong
    • This symposium will introduce the recent updates in the field of new drugs for type 2 diabetes, including SGLT2 inhibitor, GLP-1 receptor agonist and ultra-long acting insulin. In the first topic, professor Merlin C Thomas will present about SGLT2 inhibition and the potential for renal protection in type 2 diabetes. Next, professor Kyung-Mook Choi, Korea University, will discuss the cardiovascular and renal outcomes of incretin-based therapy. In the third part, professor Chang Hee Jung, University of Ulsan College of Medicine, will discuss about the properties of short- and long-acting GLP-1 analogs. Lastly, professor Hyuk Sang Kwon, the Catholic University of Korea, will talk about concepts and clinical use of new-generation ultra-long-acting basal insulin, and the possible disadvantage in its use.
Merlin C Thomas Baker IDI Heart and Diabetes Institute, Australia S1-1 SGLT2 inhibition: is there a downside?
Kyung Mook Choi Korea University, Korea S1-2 Cardiovascular & renal outcomes of incretin-based therapy
Chang Hee Jung University of Ulsan, Korea S1-3 GLP-1 receptor agonists: similarities and differences
Hyuk-Sang Kwon The Catholic University of Korea, Korea S1-4 Ultra-long acting Insulin: How long should it be?
S6 Clinical diabetes and therapeutics 2 :
Recent update on CVD risk management in type 2 diabetes
Friday 14 October 16:00~18:00 | Place: Convention hall A
Chairs: Hyoung Woo Lee , Kyung Soo Ko
    • Cardiovascular disease (CVD) is the leading cause of mortality and morbidity for patients with type 2 diabetes. Numerous studies have shown the benefit of controlling individual CV risk factors such as hyperglycemia, hypertension, dyslipidemia, obesity in preventing CVD. Recent major new clinical studies and guidelines may now change the landscape of CV risk management of T2DM. This session will deal with the contents from the basic knowledge for CV management to latest updates on the management of each CVD risk factors.
      Professor Bon-Kwon Ku (cardiologist from Seoul National University) will open the session by an overview of the comprehensive management of CVD in type 2 diabetes which is imperatively necessary for diabetologist. Professor Sung Ha Park (cardiologist from Yonsei University) will present the update on blood pressure goals since the data of SPRINT study was published. Professor Woo Je Lee (diabetologist from University of Ulsan) will address the changes of management of dyslipidemia after new ACC/AHA dyslipidemia guideline. Professor Arya M. Sharma (University of Alberta) will give a lecture about management of obesity that whether the pharmacologic treatment or surgical treatment is more helpful for obese T2DM patient. Professor Sang Youg Kim (diabetologist from Chosun University) will show the lesson from large clinical extension trials about glucose control and cardiovascular outcomes. This multidisciplinary session will be of interest to you.
Bon-Kwon Koo Seoul National University, Korea S6-1 Management of cardiovascular disease in patients with diabetes
Sung Ha Park Yonsei University, Korea S6-2 Update on blood pressure goals in T2DM (post-SPRINT era)
Woo Je Lee University of Ulsan, Korea S6-3 Are recent cholesterol treatment guidelines still controversial?
Arya M. Sharma University of Alberta, Canada S6-4 Obesity: drug or surgery
Sang Yong Kim Chosun University, Korea S6-5 Glucose control for prevention of cardiovascular disease (lesson from large clinical trials)
S10 Clinical diabetes and therapeutics 3 :
Staging and definition of metabolic disease
Saturday 15 October 08:30~10:30 | Place: Convention hall A
Chairs: Bong-Soo Cha, Arya M. Sharma
    • The definition of a disease changes over time. Based on the disease definition, we use disease staging as a classification system that uses diagnostic findings to produce clusters of patients who require similar treatment and have similar expected outcomes. Because metabolic disorders including obesity and type 2 diabetes (T2D) are heterogenous and influenced by social and economic environment, the definition and staging system of disease might be changed or progressed. For better understanding and giving insight on clustering of clinically homogeneous patients for assessment of quality of care, analysis of clinical outcomes, review of utilization of resources, and assessment of efficacy of alternative treatments, we invited 4 distinguished speakers to solve these matters.
Arya M. Sharma University of Alberta, Canada S10-1 The edmonton obesity staging system to predict mortality
Stanley Schwartz University of Pennsylvania, USA S10-2 Rationale and implications of a β-cell-centric classification of diabetes
Sin Gon Kim Korea University, Korea S10-3 MHO (metabolically healthy obesity): reality or phantom?-pros; in view of reality
Sung Hee Choi Seoul National University, Korea S10-4 MHO (metabolically healthy obesity): reality or phantom?- cons; is he a fancy cheater?
Quick Menu
Registration
Abstract
On-line submission
Venue
venue
Top